8-K: STRATA Skin Sciences Announces Clinical Study Highlighting Excimer Laser Superiority

STRATA Skin Sciences highlights a new clinical study from Japan demonstrating the superiority of narrow band excimer laser over non-narrow band UVB-source like excimer light for treating dermatologic conditions.

Summary

• STRATA Skin Sciences announced the publication of a clinical study in the Journal of Nippon Medical School, which validates the technological advantages of its high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology.
• The study demonstrates that the excimer laser penetrates deeper into hair follicles and activates more melanocyte lineage cells than excimer light, leading to superior clinical outcomes.
• Key findings include deeper penetration into hair follicles, greater activation of melanocyte lineage cells, fewer epidermal side effects, higher irradiance and shorter irradiation time, and superior laser properties for targeted treatment.
• The company has placed over 100 XTRAC devices in Japan since 2019, with 24 placed in 2024 alone, aiming to replace over 400 VTRAC Excimer Light devices previously sold in Japan.
• STRATA has sold and placed over 1,800 Excimer Laser devices in the United States and over 1,000 outside the United States.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the favorable clinical study results and the company's expansion in the Japanese market. The focus on technological superiority and improved patient outcomes contributes to a strong positive sentiment.

Positives

• The clinical study validates the technological advantages of STRATA's Excimer Laser.
• The Excimer Laser demonstrates superior clinical outcomes compared to excimer light.
• The laser's deeper penetration and greater activation of melanocyte lineage cells lead to more effective re-pigmentation.
• The Excimer Laser causes fewer epidermal side effects, resulting in a safer and more tolerable treatment experience.
• The company is expanding its presence in Japan, replacing older VTRAC Excimer Light devices with XTRAC Excimer Lasers.

Risks

• The press release includes forward-looking statements that are subject to uncertainties and changes in circumstances.
• Actual results may differ materially from the company's expectations due to financial, economic, business, competitive, market, regulatory, and other factors.
• Adverse market conditions, labor supply shortages, or supply chain interruptions could impact the company's performance.

Future Outlook

The company expects to continue developing and commercializing innovative products for the treatment of dermatologic conditions and building a leading franchise in dermatology and aesthetics.

Management Comments

• Dr. Dolev Rafaeli, President and CEO of STRATA Skin Sciences, stated that the study validates the superiority of Strata Skin Sciences' advanced technologies embedded in the XTRAC Excimer Laser.
• Dr. Rafaeli also noted the growing recognition of XTRAC's benefits for patients with vitiligo, psoriasis, alopecia areata, and atopic dermatitis in Japan.

Industry Context

The announcement highlights the ongoing advancements in dermatological treatments, specifically focusing on the superiority of laser technology over other light-based therapies. This is part of a broader trend towards more targeted and effective treatments with fewer side effects in the dermatology field.

Comparison to Industry Standards

• The document compares STRATA's XTRAC Excimer Laser to VTRAC Excimer Light devices, highlighting the former's superior technology and clinical outcomes.
• The study positions STRATA's technology as more advanced than other UVB light sources in the market.
• The company aims to replace the 400 VTRAC Excimer Light devices sold in Japan with its XTRAC Excimer Laser devices, indicating a competitive strategy to gain market share.

Stakeholder Impact

• Shareholders: The positive clinical study results and market expansion could lead to increased investor confidence.
• Patients: The superior technology offers more effective and safer treatment options for dermatologic conditions.
• Employees: The company's growth and success could create new opportunities and job security.
• Customers: Dermatologists and clinics can offer advanced treatment options to their patients.

Key Dates

Keywords

Excimer Laser, STRATA Skin Sciences, Vitiligo, Psoriasis, Alopecia Areata, Atopic Dermatitis, Dermatology, XTRAC, Clinical Study, Melanocyte